James W. Hutchings
Research Subjects
James W. Hutchings has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Matthew D. Heath
Allergy Therapeutics PLC Worthing UK
3 shared publications Murray A. Skinner
Allergy Therapeutics (UK) Ltd, Dominion Way, Worthing, West Sussex, BN14 8SA, England, UK
2 shared publications- Paul Baldrick
Product Development and Market Access Consulting, Clinical Development & Commercialisation Services, Labcorp Drug Development Inc. (formerly Covance), Harrogate, North Yorkshire, HG3 1PY, United Kingdom
2 shared publications Chris Gray
Covance Laboratories Ltd, Harrogate, North Yorkshire, UK
1 shared publication- Joe Collis
Allergy Therapeutics Ltd., Dominion Way, Worthing, BN14 8SA UK
1 shared publication - Murray A. Skinner
Allergy Therapeutics (UK) Ltd. Dominion Way, Worthing BN14 8SA, UK
1 shared publication
Latest Publications
- 1 November 2019
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 108, 104441
Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development
- 1 November 2019
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 108, 104441
Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development
- 23 June 2019
- Published by Wiley in Journal of Applied Toxicology
- Vol. 39 (10) , 1462-1469
New toxicity testing of PQ grass allergy immunotherapy to support product development
PQ Grass represents an allergen‐specific immunotherapy for pre‐seasonal treatment of patients with seasonal allergic rhinitis (or rhinoconjunctivitis) with or without mild‐to‐moderate bronchial asthma. It consists of a native pollen extract for 13 grass species, chemically modified with glutaraldehyde, and adsorbed to l‐tyrosine in a microcrystalline form with addition of the adjuvant Monophosphoryl Lipid A (MPL®). Previous non‐clinical safety testing, including rat repeat dose toxicity in adult and juvenile animals, rat reproductive toxicity and rabbit local tolerance studies showed no safety findings of concern. A new Good Laboratory Practice compliant rat subcutaneous repeat dose toxicity study to evaluate a higher clinical dose and modified posology (once every 2 weeks for 13 weeks) showed no signs of toxicity. As seen in previous studies, relatively minor, immunostimulatory effects were seen such as reversible increased white cell count (notably neutrophils), increased globulin level (resulting in decreased A/G ratio) and increased fibrinogen as well as minor dose site reaction in the form of inflammatory cell infiltrate. These findings are likely due to the immunostimulatory nature of MPL and/or the presence of l‐tyrosine within the adjuvanted vaccine. This new toxicity study with PQ Grass therefore supports longer posology with higher dose levels.
- 23 June 2019
- Published by Wiley in Journal of Applied Toxicology
- Vol. 39 (10) , 1462-1469
New toxicity testing of PQ grass allergy immunotherapy to support product development
PQ Grass represents an allergen‐specific immunotherapy for pre‐seasonal treatment of patients with seasonal allergic rhinitis (or rhinoconjunctivitis) with or without mild‐to‐moderate bronchial asthma. It consists of a native pollen extract for 13 grass species, chemically modified with glutaraldehyde, and adsorbed to l‐tyrosine in a microcrystalline form with addition of the adjuvant Monophosphoryl Lipid A (MPL®). Previous non‐clinical safety testing, including rat repeat dose toxicity in adult and juvenile animals, rat reproductive toxicity and rabbit local tolerance studies showed no safety findings of concern. A new Good Laboratory Practice compliant rat subcutaneous repeat dose toxicity study to evaluate a higher clinical dose and modified posology (once every 2 weeks for 13 weeks) showed no signs of toxicity. As seen in previous studies, relatively minor, immunostimulatory effects were seen such as reversible increased white cell count (notably neutrophils), increased globulin level (resulting in decreased A/G ratio) and increased fibrinogen as well as minor dose site reaction in the form of inflammatory cell infiltrate. These findings are likely due to the immunostimulatory nature of MPL and/or the presence of l‐tyrosine within the adjuvanted vaccine. This new toxicity study with PQ Grass therefore supports longer posology with higher dose levels.
- Open Access
- 1 January 2015
- Published by Elsevier in World Allergy Organization Journal
- Vol. 8 (1) , 21
Molecular, proteomic and immunological parameters of allergens provide inclusion criteria for new candidates within established grass and tree homologous groups
- 1 January 2015
- Published by Elsevier in World Allergy Organization Journal
- Vol. 8 (1) , 21
Open AccessMolecular, proteomic and immunological parameters of allergens provide inclusion criteria for new candidates within established grass and tree homologous groups